Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · IEX Real-Time Price · USD
43.92
+28.82 (190.86%)
Feb 27, 2024, 12:43 PM EST - Market open
190.86%
Market Cap 697.14M
Revenue (ttm) 8.47M
Net Income (ttm) -62.60M
Shares Out 46.17M
EPS (ttm) -1.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,063,927
Open 35.79
Previous Close 15.10
Day's Range 34.25 - 50.00
52-Week Range 5.65 - 50.00
Beta 1.96
Analysts Strong Buy
Price Target 37.33 (-14.96%)
Earnings Date Mar 8, 2024

About JANX

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against p... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 11, 2021
Employees 64
Stock Exchange NASDAQ
Ticker Symbol JANX
Full Company Profile

Financial Performance

In 2022, JANX's revenue was $8.61 million, an increase of 136.79% compared to the previous year's $3.64 million. Losses were -$63.06 million, 93.0% more than in 2021.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for JANX stock is "Strong Buy." The 12-month stock price forecast is $37.33, which is a decrease of -14.96% from the latest price.

Price Target
$37.33
(-14.96% downside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

Janux Therapeutics shares more than doubled in value before the bell on Tuesday after the drug developer reported encouraging interim early-stage data for its experimental therapy to treat an advanced...

4 hours ago - Reuters

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

SAN DIEGO--(BUSINESS WIRE)---- $JANX--PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors.

20 hours ago - Business Wire

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008.

7 days ago - Business Wire

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer.

7 weeks ago - Business Wire

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights.

3 months ago - Business Wire

Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights.

7 months ago - Business Wire

Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants.

8 months ago - Business Wire

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs.

8 months ago - Business Wire

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

SAN DIEGO--(BUSINESS WIRE)---- $JANX #CD28--Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development.

9 months ago - Business Wire

Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its p...

10 months ago - Business Wire

Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences.

11 months ago - Business Wire

Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

11 months ago - Business Wire

Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlight

1 year ago - Business Wire

Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc.

1 year ago - Business Wire

Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...

1 year ago - Business Wire

Janux Therapeutics to Present at Upcoming Investor Conferences in November

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...

1 year ago - Business Wire

Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprieta...

1 year ago - Business Wire

Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer

1 year ago - Business Wire

Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary tech...

1 year ago - Business Wire

Janux Therapeutics Appoints Winston Kung to Board of Directors

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary tech...

1 year ago - Business Wire

Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September

1 year ago - Business Wire

Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

1 year ago - Business Wire

Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

1 year ago - Business Wire

Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

1 year ago - Business Wire

Janux Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to ...

1 year ago - Business Wire